Sign in

Markets

Overview
News
World markets
Treasuries
Currencies
Commodities
Economy

Stocks

Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers

ETFs

Overview
Popular funds
Most active
Gainers
Losers
News

Research

Search
Sectors

(OP:RLFTY)

0.1677 UNCHANGED

Last Price Updated: 9:30 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RLFTY

< Previous 1 2 3 4 5 Next >

News headline image

MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank

March 19, 2026

Via ACCESS Newswire

News headline image

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

December 23, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

December 15, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Shareholders Approve Business Combination with NeuroX

November 14, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

October 29, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

December 16, 2024

News headline image

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

December 13, 2024

News headline image

Relief Therapeutics Publishes 2025 Half-Year Report

August 14, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Advances Publication of 2025 Half-Year Report

August 11, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

July 29, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

June 20, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

August 29, 2024

News headline image

Relief Therapeutics Secures up to $11 Million from Royalty Sales

August 04, 2024

News headline image

Relief Therapeutics Announces Results of Annual General Meeting

June 12, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

May 22, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

May 15, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

April 10, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

March 06, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

February 11, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

January 22, 2025

Via ACCESS Newswire

News headline image

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

December 27, 2024

News headline image

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

November 10, 2024

News headline image

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

November 03, 2024

News headline image

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

October 28, 2024

News headline image

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

October 24, 2024

News headline image

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

October 20, 2024

News headline image

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

October 07, 2024

News headline image

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

October 03, 2024

News headline image

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

September 17, 2024

News headline image

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

September 01, 2024

< Previous 1 2 3 4 5 Next >

© 2026 FinancialContent Services, Inc. All rights reserved.

Privacy Policy Terms of Service About

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.